Objective:
To review the use of atropine drop therapy in myopia management and its efficacy and side effects.
Key Findings:
- Low-dose atropine (0.05%) is effective for myopia management with minimal side effects.
- Initial higher doses caused significant side effects like near blur and glare.
- Patient-driven dosage adjustments are crucial for effective management.
Interpretation:
Atropine therapy presents a viable option for myopia management, particularly at lower doses, balancing efficacy and side effects.
Limitations:
- No FDA-approved low-dose atropine drops available in the U.S.
- Compounding may limit accessibility for some patients.
Conclusion:
Atropine remains a key player in myopia management, with ongoing research supporting its use at lower concentrations.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.